Compare Biogen Inc (BIIB) vs Honeywell International Inc (HON) Price & Performance

Biogen (BIIB) trades at $206.48, down 0.31% on the day, with a bullish technical signal supported by moving averages. The company reported Q2 2026 EPS of $3.60, beating estimates of $2.94, and raised full-year guidance, driven by growth in Alzheimer's and rare disease portfolios. Recent acquisitions like RayThera and Apellis bolster its pipeline. Revenue for 2025 was $9.89 billion with a net income margin of 13.07%, though margins have fluctuated year-over-year.

Outlook remains positive with strong analyst support (62.5% buy rating) and a consensus price target of $234.47, implying ~14% upside. Key risks include reliance on new drug launches to offset declining multiple sclerosis sales and integration challenges from acquisitions. Cash flow trends show variability, with 2026 projecting negative net cash flow due to significant investing activities.

Honeywell (HON) trades at $235.01, down 3.26% amid bearish technical signals and recent growth guidance concerns. The stock shows strong fundamentals with a P/E of 8.85, net margin of 21.58%, and consistent earnings beats. Recent corporate actions include a 2:1 reverse stock split and dividend payments, while business divestitures aim to sharpen focus on automation. Cash flow remains positive at $1.92B for 2025, though 2026 projections indicate a net outflow.

Outlook is mixed: valuation appears attractive with analyst consensus target of $320.54, but near-term risks include bearish technicals, debt-to-asset ratio rising to 47.66%, and potential growth deceleration. Investors may find long-term value if automation segments drive recovery, though volatility from recent spinoff underperformance warrants caution.